FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingt

on, D.C. 20549	OMB APPROVAL					
S IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287				
	Estimated average burden					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES

hours per response: 0.5

	tion 1(b).	nuc. occ		Filed	pursua or Se	nt to S ection 3	ection 80(h) o	16(a) f the I	of the	Securi ent Co	ties Exchange mpany Act of	e Act of 1 1940	934			nours	per re	esponse:	0.5
Name and Address of Reporting Person* Chinoporos Constantine				2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics, Inc. [APLT]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last)	(Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/28/2023									Officer (give title below) See R			Other (specify below)	
545 FIFTH AVENUE, SUITE 1400					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicabl Line) X Form filed by One Reporting Person						
(Street) NEW YO	(Street) NEW YORK NY 10017													Form filed by One Reporting Person Form specific and the Reporting Person					
(City)	(St	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication														
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													nded to					
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quirec	d, Dis	posed of,	or Be	nefici	ally O	wne	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)				Execution Date,		· 1	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,			1 5) Se Be O	Securities For Beneficially (D)		Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Tr	Transaction(s) (Instr. 3 and 4)				(111501.4)
Common Stock 12/28/20					.023			A		300,000(1)	A	\$0.00	300,000			D			
		Tal	ble II								osed of, c				/ned	l			
1. Title of Derivative Security (Instr. 3)	rative Conversion Date rity or Exercise (Month/Day/Year) Execution Date, if any		ition Date,	4. Transaction Code (Instr. 8) 5. Numbe of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ative rities ired osed . 3, 4	Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	lv I	(A)	(D)	Exerc	isable	Date	Title S	hares	1	- 1		- 1		1

Explanation of Responses:

1. Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 28, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date.

Remarks:

Chief Operating Officer and Chief Business Officer

/s/ Shoshana Shendelman, as 03/18/2024 attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.